SI1740698T1 - Rekombinantno modificiran plazmin - Google Patents

Rekombinantno modificiran plazmin

Info

Publication number
SI1740698T1
SI1740698T1 SI200531131T SI200531131T SI1740698T1 SI 1740698 T1 SI1740698 T1 SI 1740698T1 SI 200531131 T SI200531131 T SI 200531131T SI 200531131 T SI200531131 T SI 200531131T SI 1740698 T1 SI1740698 T1 SI 1740698T1
Authority
SI
Slovenia
Prior art keywords
domain
recombinantly modified
terminal
human plasminogen
polypeptide
Prior art date
Application number
SI200531131T
Other languages
English (en)
Inventor
Jennifer Audrey Hunt
Valery Novokhatny
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982338&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1740698(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Publication of SI1740698T1 publication Critical patent/SI1740698T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200531131T 2004-04-22 2005-04-21 Rekombinantno modificiran plazmin SI1740698T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56447204P 2004-04-22 2004-04-22
PCT/US2005/013562 WO2005105990A2 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin
EP05737862A EP1740698B1 (en) 2004-04-22 2005-04-21 Recombinantly modified plasmin

Publications (1)

Publication Number Publication Date
SI1740698T1 true SI1740698T1 (sl) 2010-11-30

Family

ID=34982338

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531131T SI1740698T1 (sl) 2004-04-22 2005-04-21 Rekombinantno modificiran plazmin

Country Status (28)

Country Link
US (2) US8034913B2 (sl)
EP (2) EP2246417B1 (sl)
JP (1) JP5026254B2 (sl)
KR (1) KR101161819B1 (sl)
CN (2) CN1961070A (sl)
AT (1) ATE476502T1 (sl)
AU (1) AU2005238464B2 (sl)
BR (1) BRPI0510063B8 (sl)
CA (1) CA2563675C (sl)
CY (1) CY1111650T1 (sl)
DE (1) DE602005022692D1 (sl)
DK (1) DK1740698T3 (sl)
EA (1) EA010784B1 (sl)
ES (2) ES2349555T3 (sl)
HK (3) HK1099341A1 (sl)
HR (1) HRP20100568T1 (sl)
IL (1) IL178343A (sl)
MA (1) MA28590B1 (sl)
MX (1) MXPA06012236A (sl)
NO (1) NO338542B1 (sl)
NZ (1) NZ550250A (sl)
PL (2) PL2246417T3 (sl)
PT (2) PT2246417E (sl)
RS (1) RS51623B (sl)
SI (1) SI1740698T1 (sl)
TN (1) TNSN06332A1 (sl)
WO (1) WO2005105990A2 (sl)
ZA (1) ZA200608498B (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070004706A (ko) 2004-02-11 2007-01-09 바이오렉스 인코포레이티드 개구리밥에서의 플라스미노겐 및 마이크로플라스미노겐의발현 방법
ES2349555T3 (es) 2004-04-22 2011-01-05 Talecris Biotherapeutics, Inc. Plasmina modificada recombinántemente.
US8231869B2 (en) * 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
HUE024916T2 (en) 2007-11-29 2016-02-29 Grifols Therapeutics Inc Recombinantly modified plasmin
KR20160110544A (ko) 2008-06-04 2016-09-21 그리폴스 테라퓨틱스 인코포레이티드 플라스민의 제조를 위한 조성물, 방법 및 키트
US9206410B2 (en) 2009-03-03 2015-12-08 Grifols Therapeutics Inc. Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom
MX2012000475A (es) 2009-07-10 2012-03-26 Thrombogenics Nv Variantes de plasminogeno y plasmina.
EP2480249B1 (en) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin for the treatment of filtration failure after trabeculectomy
BR112013017172A2 (pt) 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
AU2012296884B2 (en) 2011-08-12 2015-02-05 Thrombogenics N.V. Plasminogen and plasmin variants
TWI624267B (zh) * 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備預防或治療糖尿病性視網膜病變的藥劑上的用途及包括纖溶酶原用於預防或治療糖尿病性視網膜病變之藥劑
CA3047168A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for treating coronary atherosclerosis and complications thereof
JP7171572B2 (ja) 2016-12-15 2022-11-15 タレンゲン インターナショナル リミテッド 糖尿病を治療するための新しい方法
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
EP4137713A4 (en) 2020-04-13 2024-05-08 Fcc Kk POWER TRANSMISSION DEVICE
US20230181699A1 (en) * 2020-05-11 2023-06-15 Talengen International Limited Method and drug for treating spinal muscular atrophy
CA3196851A1 (en) 2020-11-25 2022-06-02 Grifols Worldwide Operations Limited Wound healing
US11964004B2 (en) * 2021-03-31 2024-04-23 Shenzhen Bay Laboratory Short in vivo half-life and in vivo unstable recombinant microplasmin, pharmaceutical composition comprising thereof and method of treating thromboembolism related diseases including administration thereof
WO2024018051A1 (en) 2022-07-22 2024-01-25 Grifols Worldwide Operations Limited Stable plasmin compositions for organ preservation and reconditioning

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
EP0835939B8 (de) 1990-06-28 2006-01-11 Sanofi-Aventis Deutschland GmbH Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US6613508B1 (en) * 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
CN1163619C (zh) 1996-01-23 2004-08-25 佳根基因组学公司 测定核酸分子序列的方法和组合物
JPH10158300A (ja) 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
NZ501774A (en) * 1997-07-22 2002-02-01 Qiagen Genomics Inc Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule
JP2002520367A (ja) 1998-07-14 2002-07-09 ブリストル−マイヤーズ スクイブ カンパニー アンギオスタチンのリジン結合フラグメント
EP1117437B1 (en) * 1998-09-29 2006-12-27 Leuven Research & Development vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) * 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
CA2410440A1 (en) * 2000-06-02 2001-12-13 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
DE60131450T2 (de) 2000-12-21 2008-10-16 Thrombogenics N.V. Hefeexpressionsvektor und verfahren zur herstellung eines rekombinanten proteins durch expression in einer hefezelle
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
DE10390418D2 (de) * 2002-02-06 2005-01-13 N Zyme Biotec Gmbh Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
ES2349555T3 (es) 2004-04-22 2011-01-05 Talecris Biotherapeutics, Inc. Plasmina modificada recombinántemente.
US8231869B2 (en) 2005-10-20 2012-07-31 Grifols Therapeutics Inc. Recombinant plasmin for opthalmic indications
HUE024916T2 (en) 2007-11-29 2016-02-29 Grifols Therapeutics Inc Recombinantly modified plasmin

Also Published As

Publication number Publication date
ES2349555T3 (es) 2011-01-05
CA2563675A1 (en) 2005-11-10
BRPI0510063B8 (pt) 2021-05-25
MXPA06012236A (es) 2007-01-31
HRP20100568T1 (hr) 2010-11-30
EP1740698B1 (en) 2010-08-04
BRPI0510063B1 (pt) 2020-03-17
CY1111650T1 (el) 2015-10-07
NO338542B1 (no) 2016-09-05
IL178343A (en) 2010-11-30
CN1961070A (zh) 2007-05-09
EA200601950A1 (ru) 2007-02-27
AU2005238464A1 (en) 2005-11-10
PL1740698T3 (pl) 2011-01-31
DE602005022692D1 (de) 2010-09-16
MA28590B1 (fr) 2007-05-02
ZA200608498B (en) 2008-07-30
ES2534744T3 (es) 2015-04-28
US20110318812A1 (en) 2011-12-29
CN102660564A (zh) 2012-09-12
HK1175812A1 (en) 2013-07-12
JP2007533327A (ja) 2007-11-22
PT1740698E (pt) 2010-11-02
JP5026254B2 (ja) 2012-09-12
NO20065050L (no) 2006-11-03
AU2005238464B2 (en) 2011-01-27
BRPI0510063A (pt) 2008-03-11
EP2246417B1 (en) 2015-01-21
CN102660564B (zh) 2013-05-08
US8034913B2 (en) 2011-10-11
ATE476502T1 (de) 2010-08-15
TNSN06332A1 (en) 2008-02-22
RS51623B (en) 2011-08-31
US20100304465A1 (en) 2010-12-02
KR20070006918A (ko) 2007-01-11
PT2246417E (pt) 2015-05-05
EA010784B1 (ru) 2008-10-30
WO2005105990A3 (en) 2006-01-12
US8420079B2 (en) 2013-04-16
IL178343A0 (en) 2007-02-11
PL2246417T3 (pl) 2015-06-30
KR101161819B1 (ko) 2012-07-03
NZ550250A (en) 2009-05-31
DK1740698T3 (da) 2010-10-25
WO2005105990A2 (en) 2005-11-10
EP1740698A2 (en) 2007-01-10
EP2246417A1 (en) 2010-11-03
HK1150242A1 (en) 2011-11-11
HK1099341A1 (en) 2007-08-10
CA2563675C (en) 2012-08-28

Similar Documents

Publication Publication Date Title
HK1175812A1 (en) Recombinantly modified plasmin
NZ593837A (en) Recombinantly modified plasmin
Bode The structure of thrombin: a janus-headed proteinase
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
Hata et al. Domain II of m-calpain is a Ca2+-dependent cysteine protease
TW200733970A (en) Recombinantly modified plasmin
MX2009011179A (es) Variantes de enzimas asparaginasas y sus usos.
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
UA103215C2 (uk) Поліпептид з ксиланазною активністю
Sanchez et al. A novel fibrinolytic metalloproteinase, barnettlysin-I from Bothrops barnetti (Barnett s pitviper) snake venom with anti-platelet properties
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
AU3175197A (en) Recombinant blood-coagulation proteases
EE05296B1 (et) Glkuronl-C5-epimeraas, seda kodeeriv DNA ja selle kasutamine
Oyama et al. Amino acid sequence of a thrombin like enzyme, elegaxobin, from the venom of Trimeresurus elegans (Sakishima-habu)
ATE345383T1 (de) Säugeradhäsionprotease
AU2003302901A8 (en) Human recombinant endooligopeptidase a (heopa)
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
Grundy et al. Plasminogen binds to plasmin-modulated factor Xa by Ca2+-and C-terminal lysine-dependent and-independent interactions
WO2005037202A3 (en) Methods for modulating angiogenesis
AU2001295592A1 (en) Method for synthesising peptides, peptide mimetics and proteins
WO2003085377A3 (en) Novel pancortin-pablo protein interactions and methods of use thereof